This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...
As the center of life sciences innovation increasingly shifts to China, companies must be ready for a more complex international arbitration landscape. In this...
Daniel Shack is a panelist during the session titled “Survey Says…” In recent proceedings, consumer survey evidence has been tendered. What’s it for? What’s it...
